^
Association details:
| Biomarker: | MLL rearrangement |
|---|---|
| Cancer: | Acute Lymphocytic Leukemia |
| Drug: | doxorubicin hydrochloride (Topoisomerase II inhibitor) + betulinic acid nanoformulation (APH-0202) (Maturation inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Betulinic Acid–Doxorubicin-Drug Combination Induced Apoptotic Death via ROS Stimulation in a Relapsed AML MOLM-13 Cell Model
Published date:
09/14/2021
Excerpt:
In this study, cell death regulation and induction in AML cell line from a relapsed MLL-rearranged cell model (MOLM-13) was investigated with doxorubin (Dox) and betulinic acid (BetA), singly and in combination....BetA (20 μM) and Dox (1 μM) indicated a synergistic growth inhibitory effect on MOLM-13 cells. The combined drug caused more cells to reside in irreversible late apoptotic stage compared to the single treatments (p < 0.05).
DOI:
10.3390/antiox10091456
